FAI Insert

DRUG3 trials

Sponsors

EyePoint Pharmaceuticals, Inc.

Conditions

Intermediate UveitisNon-Infectious UveitisPanuveitisPosterior UveitisUveitisUveitis, IntermediateUveitis, Posterior

Phase 3

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

CompletedNCT01694186

EyePoint Pharmaceuticals, Inc.Non-Infectious Uveitis

Start: 2013-08-02End: 2018-03-26Updated: 2021-04-02

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

CompletedNCT02746991

EyePoint Pharmaceuticals, Inc.Intermediate Uveitis, Panuveitis, Posterior Uveitis

Start: 2015-06-02End: 2019-10-04Updated: 2020-07-21

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

TerminatedNCT05070728

EyePoint Pharmaceuticals, Inc.Uveitis, Uveitis, Intermediate, Uveitis, Posterior

Start: 2021-10-13End: 2023-04-12Updated: 2024-12-19

Related Papers

The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.

2023-09-167 citations

Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis.

2021-06-1111 citations

Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.

2020-04-1770 citations